Potential Novel Therapeutics for Bipolar Disorders

Machado‐Vieira, Rodrigo; Manji, Husseini K.; Zarate, Carlos A.

doi:10.1007/7854_2010_51

Cited by 4 publications

(3 citation statements)

References 171 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2). In the light of significant evidence in support of PKC hyperactivity in BD, hypoactive DGKeta function can be hypothesized in BD [159]. In fact, DGKeta knockout mice display manic features that were ameliorated by lithium [160].…”

Section: Geneticsmentioning

confidence: 99%

Role of Protein Kinase C in Bipolar Disorder: A Review of the Current Literature

et al. 2017

View full text Add to dashboard Cite

Bipolar disorder (BD) is a major health problem. It causes significant morbidity and imposes a burden on the society. Available treatments help a substantial proportion of patients but are not beneficial for an estimated 40-50%. Thus, there is a great need to further our understanding the pathophysiology of BD to identify new therapeutic avenues. The preponderance of evidence pointed towards a role of protein kinase C (PKC) in BD. We reviewed the literature pertinent to the role of PKC in BD. We present recent advances from preclinical and clinical studies that further support the role of PKC. Moreover, we discuss the role of PKC on synaptogenesis and neuroplasticity in the context of BD. The recent development of animal models of BD, such as stimulant-treated and paradoxical sleep deprivation, and the ability to intervene pharmacologically provide further insights into the involvement of PKC in BD. In addition, the effect of PKC inhibitors, such as tamoxifen, in the resolution of manic symptoms in patients with BD further points in that direction. Furthermore, a wide variety of growth factors influence neurotransmission through several molecular pathways that involve downstream effects of PKC. Our current understanding identifies the PKC pathway as a potential therapeutic avenue for BD.

show abstract

Section: Geneticsmentioning

confidence: 99%

Role of Protein Kinase C in Bipolar Disorder: A Review of the Current Literature

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The use of tramadol as an antidepressant has not received such scrutiny. Nevertheless, its ability to function as an antidepressant has been well-documented. − …”

Section: Methodsmentioning

confidence: 99%

“…In addition to its use as an analgesic, there is substantial evidence that tramadol is an effective antidepressant. This evidence is presented and/or summarized in over 50 citations in the peer-reviewed biomedical literature in animal models, − in humans, − in the patent literature, − and in reports provided by patients. − The World Health Organization (WHO) Expert Committee on Drug Dependence published a comprehensive review of the chemistry, biochemistry, and biomedical aspects of tramadol in 2018 . Much of the background information and review material presented here concerning this medication is from this reference and references therein.…”

mentioning

confidence: 99%

Low-Dose Tramadol as an Off-Label Antidepressant: A Data Mining Analysis from the Patients’ Perspective

Bumpus

2020

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

The purpose of this analysis was to assess, from the patients' perspective, the effectiveness and relative safety of tramadol as an off-label antidepressant and to determine if patients' views and experiences are consistent with the biomedical literature. Method: A data mining approach was used to analyze databases available at drugs.com. Results: Tramadol was reported to be an effective or very effective antidepressant by 94.6% of patients (123/130) who provided ratings submitted to User Reviews for Tramadol to Treat Depression (https://www.drugs.com/comments/tramadol/ for-depression.html). When compared to 34 other antidepressants in the database titled Drugs Used to treat Depression (https://www.drugs.com/condition/depression.html), for which there were ≥100 individual reviews for each drug, tramadol was rated as being the most effective (effectiveness rating = 9.1/10). Phenelzine (effectiveness rating = 8.7/10) was the only other antidepressant having ≥100 individual reviews coupled with a very high (8.0−10.0) effectiveness rating. Eleven patients reported significant symptoms of withdrawal upon cessation of tramadol, and five patients reported loss or reduction of libido as a side effect. Most (57/72, 79.2%) patients who reported a dose consumed experienced relief from depression at low therapeutic doses (25−150 mg/day). Fourteen patients reported taking this antidepressant for 5−10 years, and four patients reported taking tramadol for 10 or more years. Results demonstrated that most patients' comments and beliefs are consistent with the biomedical literature. Conclusions: Patients' reviews coupled with a survey of the biomedical literature indicate that at low therapeutic doses in the absence of interactions with other drugs, adult patients found tramadol to be a generally safe, effective, and fast-acting medication for relief from depression.

show abstract

Modulation of neural circuits by melatonin in neurodegenerative and neuropsychiatric disorders

Giri,

Mehan,

Khan

et al. 2024

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Potential Novel Therapeutics for Bipolar Disorders

Cited by 4 publications

References 171 publications

Role of Protein Kinase C in Bipolar Disorder: A Review of the Current Literature

Role of Protein Kinase C in Bipolar Disorder: A Review of the Current Literature

Low-Dose Tramadol as an Off-Label Antidepressant: A Data Mining Analysis from the Patients’ Perspective

Modulation of neural circuits by melatonin in neurodegenerative and neuropsychiatric disorders

Contact Info

Product

Resources

About